Talks between SsangYong and HAAH likely to collapse Debt-ridden automaker is unlikely to find another buyer
Translated by Ryu Ho-joung 공개 2021-04-05 08:15:03
이 기사는 2021년 04월 05일 08시09분 thebell에 표출된 기사입니다
SsangYong Motor is unlikely to find another buyer if discussions between the ailing automaker and U.S.-based HAAH Automotive Holdings collapse, which could result in the liquidation of the company.The Seoul bankruptcy court has asked the automaker to update on the progress in negotiating with a potential buyer, industry sources said.
In December last year, SsangYong applied for the bankruptcy court's autonomous restructuring support program and was originally given until February 28 to find a solution with creditors. The deadline was extended to March 2, which also already expired.
SsangYong has been in talks with HAAH over the sale over the past months. But there has been little progress with many expecting the U.S. company to pull out eventually.
The automaker initially sought to submit a reorganization plan with the court to file for a prepackaged bankruptcy that will reduce its debt burden. This required the nod of creditors holding more than half of the company’s debt. SsangYong is unlikely to get consent from creditors if it fails to reach an agreement with HAAH.
The collapse of the deal would force SsangYong to go through rehabilitation proceedings that will be supervised by the court, where the automaker will find a new buyer or start a process to liquidate the company. But chances for the former are seen as slim because HAAH was considered the only candidate with an intention to buy.
The collapse of SsangYong revived memories in the restructuring industry of Pantech. The mobile phone manufacturer filed for bankruptcy protection in 2014 but could not find a buyer. Its rehabilitation efforts ultimately failed. (Reporting by Seon-young Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나